FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	
------------------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
houre per reenonce.	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hudson Frederick M.					SU	2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN]								neck all X D	ationship of Reportir k all applicable) Director Officer (give title			son(s) to Iss 10% Ov Other (s	wner
(Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE					Date of Earliest Transaction (Month/Day/Year) 02/22/2024 If Amendment, Date of Original Filed (Month/Day/Year)									below)		below)		specify	
				4. 1									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) ROCKVILLE MD 20850													X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)		- Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										ed to			
		Tab	le I - Nor	ı-Deri	vative	e Se	curitie	s Ac	cquired,	Dis	posed o	of, or Be	neficia	lly Ow	ned	l			
1. Title of Security (Instr. 3) 2. Trans Date (Month/li				2A. Deemed Execution Date, if any (Month/Day/Year			Code (Instr. 5)				d Sed Bei Ow		s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D) Price		Tra	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock													33,	33,231		D			
		7							quired, Di s, option					y Own	ed				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date Execution Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)		Date,	4. Transaction Code (Instr 8)				6. Date Exe Expiration (Month/Day	Date	Amount of		f g Security				illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Director Stock Option (Right to Buy)	\$27.94	02/22/2024			A		8,252		(1)	0:	2/22/2034	Common Stock	8,252	\$0		8,252		D	
Restricted Stock Units	(2)	02/22/2024			A		5,369		(3)		(3)	Common Stock	5,369	\$0		5,369		D	

Explanation of Responses:

- 1. The option vests on February 22, 2025.
- 2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- 3. These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025.

/s/ Timothy C. Dec, as attorney-in-fact

02/26/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.